BrightInsight and Sanofi Report Improved Adherence Outcomes From Patient App Developed for Biologic Therapy

BrightInsight has released new data from its collaboration with Sanofi and its partner Regeneron, indicating that a digital Patient App developed for a key biologic therapy has delivered measurable improvements in patient adherence and persistence. The findings address long-standing challenges in the pharmaceutical industry, particularly for self-injected therapies administered at home.

Adherence and persistence remain persistent concerns across chronic and specialty treatments. Industry data cited by the companies indicate that adherence rates can fall as low as 50%, with additional drop-off after the first year of therapy. Persistence rates are similarly affected, with between 35% and 63% of patients discontinuing treatment within the first year. Against this backdrop, BrightInsight and Sanofi partnered to design a digital solution intended to provide targeted, drug-specific support through a patient-centered interface.

The Patient App was built specifically to support patients using one of Sanofi and Regeneron’s biologic therapies. According to BrightInsight, the app integrates personalized guidance with a simplified digital experience aimed at supporting patients throughout their treatment journey. Since its limited launch, more than 25,000 patients have adopted the app, reflecting early uptake across supported indications.

An analysis of real-world observational data from more than 6,000 patients across multiple indications and cohorts demonstrated improved outcomes among Patient App users. The data showed a 4% lower discontinuation rate after one year for patients using the app compared with those who did not. The analysis also found an improvement in adherence at the one-year mark, suggesting that digitally enabled, therapy-specific support may contribute to sustained treatment engagement.

Kal Patel, CEO and Co-Founder of BrightInsight, said, “We’re honored that Sanofi and its partner, Regeneron, have trusted BrightInsight with the patient experience of a critical medicine.” He added, “While patient apps have historically had limited impact, we’ve helped Sanofi and its partner Regeneron build a transformative digital solution that truly understands the patient’s disease journey—and paves the way for meaningful expansion, across cohorts, indications, and geographic regions.”

Based on user feedback and observed outcomes, Sanofi is expanding its partnership with BrightInsight into additional international markets. The expansion will leverage the BrightInsight Platform’s global capabilities and extend the collaboration across Sanofi’s specialty care portfolio.

Emmanuel Frenehard, Chief Digital Officer at Sanofi, said, “At Sanofi, we’re committed to transforming the patient experience through scalable, high-impact digital solutions.” He continued, “With BrightInsight, we’ve developed a solution for patients that also delivers measurable impact in therapy adherence and persistence.”

Click here for the original news story.